Repligen (RGEN) is a "bioprocessing-focused life sciences company" which sounds way above my pay grade. Shares of RGEN soared from $165 in May to short of $330 in late September. A double in five months has my attention. Let's check out the charts.
More from Investing
After its parent, Sina Corp., delisted in New York, Weibo could be next now that its stock has established a Chinese presence.
Plus, One must ask themselves... Are Russia and China satisfied with making Ukraine and Taiwan uncomfortable? Do they understand the costs?
The market is grappling with the acceleration of the Fed tapering off its bond buying and the potential for interest rate hikes in 2022.
The short answer is yes, as the shares of cosmetics maker Estee Lauder have shown over the years when they've become overvalued.
Stocks correct when they get overdone and then rally when they get oversold and everyone gets too bearish. Too simplistic? Let's check the charts and indicators.